Vitamin D3 for Life

Live Enlightened

Physiology

Vitamin D, Endothelial Inflammation and Immune-Cell Adhesion: Full Study

Previous related pageVitamin D, Endothelial Inflammation and Immune-Cell Adhesion: Study SummaryNext related pageVitamin D, Endothelial Inflammation and Immune-Cell Adhesion: Study Summary
Study at a glance

Can active vitamin D change how immune cells attach to blood-vessel linings?

Two laboratory studies tested how active vitamin D affects inflammation in the cells lining blood vessels. One measured proteins involved in immune-cell attachment. The other measured whether immune cells actually attached. Both used cells grown in the laboratory and an inflammatory challenge. Neither tested ordinary vitamin D supplements in people or measured heart attacks and strokes.

Did active vitamin D change proteins involved in immune-cell attachment?

Giving active vitamin D before the inflammatory challenge reduced two attachment-related proteins and changed some cell signals. Reducing the vitamin D receptor, the protein that receives its signal, weakened some of these effects. However, one reported result did not fit the proposed mechanism, and the number of independent cell preparations was unclear. The study did not directly show that fewer immune cells attached.

Did active vitamin D reduce actual immune-cell attachment?

Researchers added a laboratory immune-cell line to blood-vessel lining cells and measured attachment. Active vitamin D did not significantly reduce attachment at the tested concentrations, whether given with the inflammatory challenge or afterwards. This study used three independent experiments. It tested a stronger inflammatory challenge and different timing from the first study, so it was not a direct repeat of the same experiment.

Do these cell experiments show healthier circulation?

Lower amounts of an attachment-related protein do not automatically mean less actual attachment or healthier circulation. The second study did not prove that every small effect was absent, but its negative finding must be retained. The experiments cannot identify which design difference explains their different results. They also cannot establish a blood vitamin D target, supplement dose or protection against heart and blood vessel disease.

Read the full article below ↓

Can vitamin D signalling reduce the inflammatory changes that help immune cells attach to the lining of blood vessels? Two laboratory papers published in 2025 give different answers to different parts of that question. One reports changes in endothelial inflammatory signals and adhesion-molecule expression. The other directly tests monocyte attachment and finds no reduction under its experimental conditions. Together they support a qualified examination of a proposed cardiovascular pathway, rather than a claim of cardiovascular protection. For the shorter account, read Vitamin D, Endothelial Inflammation and Immune-Cell Adhesion: Study Summary.

The specific endothelial function being tested

Endothelial cells form the inner lining of vessels. When these cells respond to inflammatory signals, they can change the proteins through which circulating immune cells interact with the vessel wall. This is one part of endothelial function. It is distinct from maintaining a tight barrier, producing a relaxing signal or repairing an injured vessel. A favourable measurement of one function does not establish improvement in the others.

Monocytes are circulating immune cells. Their attachment to activated endothelium is relevant to inflammatory recruitment, including processes investigated in atherosclerosis. Attachment alone is not plaque formation: movement through the vessel wall, lipid accumulation, persistence of inflammation and changes within the plaque involve additional steps. The present studies examine early cellular events. Neither measures atherosclerotic plaque progression, heart attacks or strokes in people.

Tumour necrosis factor alpha, abbreviated TNF-α, was the inflammatory stimulus in both experiments. It can activate nuclear factor kappa B, or NF-κB, a family of proteins involved in controlling gene expression. The p65 component is one part of that system. The inflammatory signalling overview explains why the timing and strength of a signal matter. An experiment that changes this pathway is testing a defined response to a challenge, not measuring the total burden of inflammation throughout a person.

Xia and colleagues: molecular responses in cultured cells

Xia and colleagues used cultured human umbilical vein endothelial cells, commonly abbreviated HUVECs. These are cells of human origin, but this was not a human clinical trial. The cells were at passages three to four, meaning they had undergone a limited number of culture transfers. The principal protocol applied calcitriol, the active vitamin D hormone, before stimulation with TNF-α. Calcitriol is chemically and physiologically distinct from taking cholecalciferol, the vitamin D3 found in ordinary supplements.

The principal treatment sequence used 30 minutes of calcitriol pretreatment followed by TNF-α at 40 ng/mL for 24 hours, with other timings specified for particular assays. Calcitriol concentrations ranged from 1 to 100 nanomolar, and the authors reported the strongest suppression at 10 nanomolar. Those are concentrations in culture medium, not doses to give a person. The fluorescence-localisation experiment used a different schedule, so its images should not be described as another measurement from the identical 24-hour protocol.

The researchers measured vascular cell adhesion molecule 1, or VCAM-1, and E-selectin. Both participate in interactions between immune cells and the vessel lining. They assessed messenger RNA, the intermediate instructions for making proteins, and protein abundance. TNF-α increased these markers, while calcitriol pretreatment reduced their expression. Lower abundance of an adhesion-related protein is a molecular result. The study did not directly establish that fewer monocytes attached to the endothelial layer.

What the receptor experiments add, and what remains uncertain

The team reduced vitamin D receptor expression using small interfering RNA, a method that reduces production of a selected protein. In the adhesion-marker experiments, this weakened the suppressive response attributed to calcitriol. The vitamin D receptor explanation supplies the relevant background: receptor availability is part of the cell’s ability to respond to an active hormone. Interfering with that receptor can help investigate a mechanism, but it is not the same intervention as lowering a patient’s vitamin D intake.

Additional assays examined chemical activation of NF-κB-related proteins and the association of p65 with the regulatory regions of the VCAM-1 and E-selectin genes. An NF-κB inhibitor also reduced adhesion-marker expression. These experiments make the proposed connection more specific than a simple observation that two measurements moved together. Nevertheless, inhibiting a pathway and changing a receptor do not by themselves establish that every downstream effect is mediated exclusively through the same molecular interaction.

There is an important internal qualification. Figure 3’s nuclear-p65 measurements do not show the straightforward reversal by receptor knockdown that a simple receptor-dependent suppression account would predict. The plotted knockdown condition is lower, rather than restored toward the TNF-α condition, and the associated prose is difficult to reconcile with the broader narrative. This review therefore does not present that figure as a clean demonstration of the proposed causal sequence. The discrepancy needs clarification rather than an invented correction.

A separate protein-association assay recovered more p65 with the vitamin D receptor after calcitriol exposure. Such an assay supports association within the recovered protein complex. It does not prove direct physical binding between purified proteins or establish that sequestration of p65 is the only explanation for the gene-expression changes. The main report and figure legends also do not clearly establish the number of independent biological preparations underlying every comparison. Multiple measurements within a preparation cannot substitute for independent replication.

Marino and colleagues: measuring attachment itself

Marino and colleagues combined HUVECs with THP-1 cells, a laboratory monocyte cell line. This model allowed a functional adhesion assay: fluorescently labelled monocytes were added to the endothelial cultures, non-adherent cells were washed away, and the remaining fluorescence represented attachment. It therefore moved closer to the cellular interaction of interest than measuring adhesion-related RNA alone. It still lacked the full architecture, flowing blood and mixed immune-cell population of an intact human vessel.

The researchers tested calcitriol from 0.1 to 100 nanomolar with a stronger TNF-α stimulus, 100 ng/mL. One protocol added calcitriol together with TNF-α and monocytes for 24 hours. In the second, inflammatory exposure and monocyte contact began first; calcitriol was added after 24 hours and assessed after another 24 hours. Neither protocol was equivalent to Xia’s short pretreatment followed by a lower concentration of TNF-α.

TNF-α increased monocyte adhesion relative to the unstimulated control. Calcitriol did not significantly reduce adhesion across the tested concentrations in either protocol. In Figures 2 and 4, adhesion is approximately twice the unstimulated baseline, and calcitriol-treated cultures remain near that level. This is a visual description of the plotted response, not an exact extracted effect estimate. Each adhesion experiment used three independent experiments with seven technical replicates per concentration. That is not evidence from 21 independent donors or 21 patients, and technical repeat measurements should not be counted that way. The bars show means with standard errors of the mean. Comparisons used one-way analysis of variance followed by least-significant-difference tests, with a significance threshold of P<0.05.

The authors also measured soluble VCAM-1, E-selectin and cluster of differentiation 15, or CD15, in culture supernatants, the liquid surrounding the cells. TNF-α increased soluble VCAM-1, and calcitriol did not significantly reduce it. E-selectin and CD15 did not show a clearly established increase after the inflammatory stimulus in these assays. Their null treatment comparisons therefore need a different interpretation from a marker that first showed a convincing stimulated response. Soluble concentrations do not directly measure how much adhesion protein is displayed on the cell surface.

How strong is the null result?

The adhesion findings directly limit the broad claim that calcitriol necessarily prevents immune-cell attachment whenever endothelial cells encounter an inflammatory stimulus. They do not establish mathematical equivalence between every treatment and control. With only three independent experiments, a nonsignificant comparison cannot exclude every small effect. Nor can this experiment determine whether another stimulus, timing, cell preparation or concentration would produce a different response. Those possibilities are questions for testing, not reasons to recast the observed null finding as a positive one.

The study used endothelial cells across passages five to fifteen. Culture history can affect cellular behaviour, adding another difference from the earlier-passage model used by Xia. The authors acknowledged that the strong TNF-α challenge might obscure subtler effects, but they did not demonstrate that this explained the result. Their viability-method paragraph also gives micromolar units where the viability tables and results use nanomolar units. That reporting discrepancy prevents treating the viability protocol as unambiguously specified; it does not justify silently changing the units.

Why the papers cannot be combined into one effect estimate

ComparisonXia and colleaguesMarino and colleagues
Main questionInflammatory signalling and adhesion-marker expressionActual monocyte attachment and soluble markers
Cell settingEndothelial cells aloneEndothelial cells with a monocyte cell line
TimingPretreatment, with assay-specific schedulesConcurrent treatment or treatment after stimulation
Main qualificationAn internally inconsistent receptor-mechanism result and unclear biological replicationNo demonstrated adhesion reduction in a small, strongly stimulated model

The apparent disagreement is informative because the outcomes occupy different steps in the proposed pathway. A treatment could change expression of selected proteins without changing net attachment, which depends on interactions among several molecules and cell types. Conversely, a null adhesion assay does not erase a molecular response observed under another protocol. These two papers cannot identify which experimental difference caused their divergence because they did not compare all those conditions within one coordinated experiment.

The connection with immune modulation also requires care. Immune-cell recruitment can contribute to injury, but it also supports defence and tissue responses. Less attachment is not automatically better in every setting. Marino’s null result does not prove preservation of healthy immunity, just as Xia’s lower adhesion-marker expression does not prove improved cardiovascular health. Both interpretations would require outcomes beyond those measured.

The boundary between a risk pathway and clinical protection

Inflammatory activation is one aspect of vascular biology. Vascular tone concerns contraction and relaxation of the vessel wall. Neither paper measured vessel diameter, stimulated dilation or blood delivery to an organ. A cell-adhesion result should therefore not be relabelled improved circulation, and it does not reproduce evidence about endothelial barrier permeability. Keeping those endpoints separate gives each experiment a useful, limited role.

Likewise, vitamin D status and vitamin D effect are different quantities. A blood measurement of 25-hydroxyvitamin D is not the calcitriol concentration applied to a culture dish, nor a direct measure of endothelial receptor activity. These experiments cannot define a blood target or a supplement regimen. Their compound, delivery and controlled cellular environment differ fundamentally from nutritional replacement in a person.

The guide to evidence hierarchies helps match conclusions to questions. The defensible finding here is that selected endothelial inflammatory responses can change after calcitriol exposure, while a separate functional adhesion model found no corresponding reduction in attachment. The proposed receptor pathway remains qualified by the first paper’s reporting inconsistency. Demonstrating cardiovascular prevention would require direct clinical evidence, not an uninterrupted chain of assumptions from a cell marker to a disease outcome.

Scientific sources

Xia Y, Liu S, Shao Q, Feng Y, Jin B, Zhang Q. 1α, 25-dihydroxyvitamin D3 attenuates tumor necrosis factor-α-induced endothelial cell injury by modulating the tumor necrosis factor-α/nuclear factor kappa-B pathway. CytoJournal. 2025;22:70. DOI: 10.25259/Cytojournal_220_2024. PMID: 41216236. Endothelial signalling experiment; interpret the receptor mechanism with the reporting qualifications discussed above.

Marino M, Venturi S, Møller P, Rendine M, Martini D, Riso P, Del Bo’ C. Vitamin D does not mitigate monocyte adhesion to vascular endothelial cells in an in vitro pro-inflammatory model. PharmaNutrition. 2025;34:100454. DOI: 10.1016/j.phanu.2025.100454. The university record identifies the publication and links its published version; the complete author-uploaded article was also examined.

Related reading

Original sources

Source

1α, 25-dihydroxyvitamin D3 attenuates tumor necrosis factor-α-induced endothelial cell injury by modulating the tumor necrosis factor-α/nuclear factor kappa-B pathway

Published in CytoJournal (2025).

Publication details

Xia Y, Liu S, Shao Q, Feng Y, Jin B, Zhang Q. 1α, 25-dihydroxyvitamin D3 attenuates tumor necrosis factor-α-induced endothelial cell injury by modulating the tumor necrosis factor-α/nuclear factor kappa-B pathway. CytoJournal. 2025;22:70. DOI: 10.25259/Cytojournal_220_2024. PMID: 41216236. Endothelial signalling experiment; interpret the receptor mechanism with the reporting qualifications discussed above.

Read more →
Source

Vitamin D does not mitigate monocyte adhesion to vascular endothelial cells in an in vitro pro-inflammatory model

Published in PharmaNutrition (2025).

Publication details

Marino M, Venturi S, Møller P, Rendine M, Martini D, Riso P, Del Bo’ C. Vitamin D does not mitigate monocyte adhesion to vascular endothelial cells in an in vitro pro-inflammatory model. PharmaNutrition. 2025;34:100454. DOI: 10.1016/j.phanu.2025.100454. The university record identifies the publication and links its published version; the complete author-uploaded article was also examined.

Read more →